Spexin, a novel regulator of lipid & carbohydrate metabolism, is a potential therapeutic for obesity, type 2 diabetes mellitus, & non-alcoholic fatty liver disease.
AASLD LiverLearning®, Paul Berk,
Pharmacokinetics (PK), safety and tolerability of the 2- and 3-direct acting antiviral (DAA) combination of AL-335, odalasvir (ODV) and simeprevir (SMV) administered once-daily (QD) in healthy volunteers (HVs)
AASLD LiverLearning®, Thomas Kakuda,
Association of T-Cell Exhaustion Markers, PD-1, TIM-3 and LAG-3 with Liver Cirrhosis, and Responses to Therapy in Chronic HCV-Infected Patients
AASLD LiverLearning®, Enass Abdel-Hameed,